Skip to Content

Ph2 study of neoadjuvant in subjects with FRa-Expressing fallopian tube or peritoneal cancer

Phase II Clinical Trial

A Single-Arm Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FRα-Expressing Advanced-Stage Serous Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer(M25-231)

Indication: Ovarian Cancer
Trial Number: 06890338
Trial Status: OPEN

Participating Locations